% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • swhitemd50 swhitemd50 Jan 21, 2012 1:35 PM Flag

    Impossible to place a value on Vertex

    Approval of Kalydeco is all but assured based on the completed clinical studies showing excellent efficacy in the G551 mutation and virtually no adverse events. The NDA also has priority review from the FDA for an unmet medical need. The stock price may see a small bump with the approval but nothing significant from Kalydeco until actual sales and revenues are reported. Of course, if Vertex reports positive data from the combination Kaydeco/VX-809 studies for the more common CF mutation that is applicable to 90% of CF patients, that would be a game changer and the stock could soar.

126.30+0.70(+0.56%)May 4 4:00 PMEDT